A total of 56.0% of patients reported Grade 3 or higher treatment-related adverse events (TRAEs), including neutropenia, leukopenia, thrombocytopenia, anemia, rash, and increased alanine aminotransferase, alkaline phosphatase, and γ-glutamyl transferase, which were mainly related to chemotherapy (Supplementary Table 2, Supplementary Fig. 3a). The gene discussed is GPT; the disease is neutropenia.